CELL INTELLIGENCE · 肿瘤细胞治疗研究

多发性骨髓瘤感染风险增加的免疫生物标志物

Immune biomarkers of increased infection risk in multiple myeloma.

从静态风险到动态疾病监测：MRD 与免疫图谱在多发性骨髓瘤中的作用

From static risk to dynamic disease monitoring: the role of MRD and immune profiling in multiple myeloma.

骨髓 NK 细胞谱预测接受 daratumumab 为基础治疗的多发性骨髓瘤患者的 MRD 阴性

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.

溶瘤牛疱疹病毒 1 型诱导免疫微环境重塑并增强多发性骨髓瘤的治疗反应

Oncolytic bovine herpesvirus type 1 induces immune microenvironment remodeling and enhances treatment responses in multiple myeloma.

复发难治性多发性骨髓瘤中对达雷妥尤单抗为基础治疗耐药的基因组和免疫决定因素

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma.

运动动员的淋巴细胞通过 CD16(+) NK 细胞介导的细胞毒性增强多发性骨髓瘤的抗体免疫治疗

Exercise-mobilized lymphocytes enhance antibody-based immunotherapy in multiple myeloma through CD16(+) NK cell-mediated cytotoxicity.

这些发现表明，急性运动可动员一种强效的 NK 细胞亚群，该亚群能增强单克隆抗体对骨髓瘤细胞的疗效。这些发现还凸显了在 MM 中精准把握时机、结合具体情境地整合运动，以优化单克隆抗体疗效的潜力。

KDM6A 对 CD38/CD48 的表观遗传调控介导多发性骨髓瘤中的 NK 细胞反应

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma.

多发性骨髓瘤患者对 SARS-CoV-2 二价加强针疫苗接种次优免疫应答相关的细胞机制

Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.

我们的研究强调了 MM 患者在接受二价 COVID-19 疫苗接种后观察到的不同免疫反应。具体而言，一部分接受抗 CD38 和抗 BCMA 治疗的 MM 患者经历免疫细胞如 DCs、B 细胞、NK 细胞和 TFH 细胞的损伤，导致无法对疫苗接种产生足够的体液和细胞反应。

通过单细胞测序鉴定复发/难治性多发性骨髓瘤中 BCMA CAR-T 治疗后复发的潜在耐药机制和治疗靶点

Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myelom

NK 细胞表型与复发/难治性多发性骨髓瘤中达雷妥尤单抗应答和耐药相关

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.